Therapy of Sjogren's syndrome - New aspects and future directions

Vlachoyiannopoulos, PG

dc.contributor.author	Vlachoyiannopoulos, PG	en
dc.date.accessioned	2014-03-01T01:47:44Z
dc.date.available	2014-03-01T01:47:44Z
dc.date.issued	1998	en
dc.identifier.issn	0003-410X	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/25304
dc.subject	Sjogren's syndrome	en
dc.subject	therapy	en
dc.subject.classification	Medicine, General & Internal	en
dc.subject.other	KERATOCONJUNCTIVITIS SICCA	en
dc.title	Therapy of Sjogren's syndrome - New aspects and future directions	en
heal.type	journalArticle	en
heal.language	English	en
heal.publicationDate	1998	en
heal.abstract	Therapy of Sjogren's syndrome remains empirical and symptomatic. The main goals are to treat the disease related features, especially sicca manifestations, since the immunosuppressive therapy has not given promising results. For the treatment of keratoconjunctivitis sicca: local stimulators of tear secretion, protective bicarbonate buffered solutions, replacement therapy or supportive operative procedures should be tried. For oral manifestations: stimulators of salivary secretion such as pilocarpine, or agents changing the consistency of saliva such as bromhexine orally should be tried. Saliva substitutes have a transient effect. Frequent ingestion of sugar free liquids may help. Oral hygiene is important to avoid oral candidiasis and dental caries. Treatment of parotid gland swelling is not necessary. Pulmonary manifestations include pulmonary infiltrates in perialveolar areas, nodular or cavitary lesions which may represent lymphoma. Hilar adenopathy, solid or cavitary lesions should be biopsed. In case of vasculitis prednisolone 1mg/kg/day with progressive tapering should be tried. Renal involvement is manifested mainly as interstitial disease. Administration of NaHCO3 or sodium citrate is important to prevent acidosis and nephrocalcinosis. Vasculitis, when it is of the leukoclasic form, does not need therapy; when it is manifested with severe major organ involvement corticosteroids and/or cytotoxic therapy should be tried. Lymphoma is treated as in the patients without Sjogren's in close collaboration with the oncology department.	en
heal.publisher	MASSON EDITEUR	en
heal.journalName	ANNALES DE MEDECINE INTERNE	en
dc.identifier.isi	ISI:000072986700011	en
dc.identifier.volume	149	en
dc.identifier.issue	1	en
dc.identifier.spage	49	en
dc.identifier.epage	53	en